Oncorus is a pre-clinical stage biotechnology company developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit all arms of immune system to treat solid tumors.
For more details on financing and valuation for Oncorus, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
ONCR
0.36 as of 3/20/23
To read this article and more news on Oncorus, register or login.